United States · Series A startup

Who invested in AsclepiX Therapeutics

One round we have observed, with the 2 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$10Mraised across 1 round since 2023, from 1 source

Latest round
Series A, $10MJul 2023
Investors
2
See who backed them

The rounds

  1. Jul 2023
    Series A$10M

    Source recorded

Founders and team

From the SEC filings it signed: 5 on the team.

  • Aleksander PopelExecutive Officeri
  • Amir ShojaeiExecutive Officeri
  • Jill TierneyExecutive Officeri
  • Niranjan PandeyExecutive Officeri
  • Robert DempseyExecutive Officeri

On the board, as filediBen AskewChris GarabedianJordan GreenJosh BarerSapna SrivastavaSteven Altschuler

Everyone who backed them

Perceptive AdvisorsAsset manager1round
TEDCOVC firm1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about AsclepiX Therapeutics

Who invested in AsclepiX Therapeutics?

AsclepiX Therapeutics's investors include Perceptive Advisors and TEDCO.

How much has AsclepiX Therapeutics raised?

AsclepiX Therapeutics has raised $10M across 1 round since 2023.

When did AsclepiX Therapeutics last raise?

AsclepiX Therapeutics's most recent round was a Series A of $10M in Jul 2023.

What was AsclepiX Therapeutics's biggest round?

Its most recent round, $10M in Jul 2023, is also its largest on record.

Who backed AsclepiX Therapeutics first?

AsclepiX Therapeutics's first round on record, in Jul 2023, was backed by Perceptive Advisors and TEDCO.

What stage is AsclepiX Therapeutics at?

AsclepiX Therapeutics's latest named round is a Series A, in Jul 2023.

Where is AsclepiX Therapeutics based?

AsclepiX Therapeutics is based in the United States.

Companies like AsclepiX Therapeutics

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.